← Leaderboards
Sotirios Tsimikas
University Of California San Diego
$7,692,120
Attributed
$7,692,120
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,692,120 · 6
By mechanism
R01$6,806,062 · 3
P01$566,918 · 1
K08$319,140 · 1
M01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Diego
Same institution · by research overlap
- Joseph L Witztum$27,414,786
- John A Frangos$16,932,388
- Wulf Palinski$6,771,384
- Paul J Mills$14,704,223
- Andrew C Li$2,146,234
Others in their field
Top investigators on “Myocardial Infarction”
- Judith S Hochman · New York University School Of Medicine$121,330,744
- Paul M. Ridker · Brigham And Women'S Hospital$57,742,470
- Gervasio A Lamas · Mount Sinai Medical Center (Miami Beach)$57,397,502
- Pamela Susan Douglas · Duke University$51,876,470
- Julie E Buring · Brigham And Women'S Hospital$46,647,558
- Walter N Kernan · Yale University$42,197,025
Research focus
Myocardial InfarctionCardiovascular Disorder RiskPhospholipidsLipidsLaboratoriesEventClinical ResearchCardiovascular DiseasesDiagnosis Design /EvaluationCardiovascular SystemClinical DataAtherosclerosisLipoprotein (A)Coronary ArteryAntibody SpecificityHeart RevascularizationAntibodiesBiomarkerHeart Disorder DiagnosisHeart TransplantationAngina PectorisBlood Vessel ProsthesisArterial Fatty StreakBlood Chemistry
Grant awards (29)
Aspirin, Lp(a) and Primary Prevention of Cardiovascular Events$774,023
R01 · FY2025 · HL · contact PI
Translating Lp(a) biology to clinical applications$627,699
R01 · FY2025 · HL · contact PI
Aspirin, Lp(a) and Primary Prevention of Cardiovascular Events$757,829
R01 · FY2024 · HL · contact PI
Translating Lp(a) biology to clinical applications$615,146
R01 · FY2024 · HL · contact PI
Aspirin, Lp(a) and Primary Prevention of Cardiovascular Events$763,547
R01 · FY2023 · HL · contact PI
Translating Lp(a) biology to clinical applications$627,699
R01 · FY2023 · HL · contact PI
Translating Lp(a) biology to clinical applications$649,019
R01 · FY2022 · HL · contact PI
Core B: Immunoassay Core$112,783
P01 · FY2021 · HL · contact PI
Core B: Immunoassay Core$112,640
P01 · FY2020 · HL · contact PI
Core B: Immunoassay Core$112,640
P01 · FY2019 · HL · contact PI
Core B: Immunoassay Core$112,635
P01 · FY2018 · HL · contact PI
Oxidation-specific nanoparticles for imaging atherosclerosis$402,965
R01 · FY2017 · HL · contact PI
Core B: Immunoassay Core$116,220
P01 · FY2017 · HL · contact PI
Oxidation-specific nanoparticles for imaging atherosclerosis$402,965
R01 · FY2016 · HL · contact PI
Oxidation-specific nanoparticles for imaging atherosclerosis$396,920
R01 · FY2015 · HL · contact PI
Oxidation-specific nanoparticles for imaging atherosclerosis$394,905
R01 · FY2014 · HL · contact PI
Oxidation-specific nanoparticles for imaging atherosclerosis$393,345
R01 · FY2013 · HL · contact PI
IMAGING ATHEROSCLEROSIS WITH SPECIFIC ANTIBODIES$106,380
K08 · FY2002 · HL
IN VITRO ASSESSMENT OF LIPID PEROXIDATION IN CARDIAC PATIENTS$0
M01 · FY2002 · RR
IN VITRO ASSESSMENT OF LIPID PEROXIDATION IN CARDIAC PATIENTS$0
M01 · FY2002 · RR
IN VITRO ASSESSMENT OF LIPID PEROXIDATION IN CARDIAC PATIENTS$0
M01 · FY2002 · RR
IN VITRO ASSESSMENT OF LIPID PEROXIDATION IN CARDIAC PATIENTS$0
M01 · FY2002 · RR
IMAGING ATHEROSCLEROSIS WITH SPECIFIC ANTIBODIES$106,380
K08 · FY2001 · HL
IN VITRO ASSESSMENT OF LIPID PEROXIDATION IN CARDIAC PATIENTS$0
M01 · FY2001 · RR
IN VITRO ASSESSMENT OF LIPID PEROXIDATION IN CARDIAC PATIENTS$0
M01 · FY2001 · RR
IMAGING ATHEROSCLEROSIS WITH SPECIFIC ANTIBODIES$106,380
K08 · FY2000 · HL
IN VITRO ASSESSMENT OF LIPID PEROXIDATION IN CARDIAC PATIENTS$0
M01 · FY2000 · RR
IN VITRO ASSESSMENT OF LIPID PEROXIDATION IN CARDIAC PATIENTS$0
M01 · FY2000 · RR
IN VITRO ASSESSMENT OF LIPID PEROXIDATION IN CARDIAC PATIENTS$0
M01 · FY2000 · RR